valproic acid has been researched along with Hypomania in 16 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
| Excerpt | Relevance | Reference |
|---|---|---|
| " There is little evidence indicating the efficacy of celecoxib adjuvant therapy in treatmenting of manic episodes of bipolar disorder." | 9.69 | Does celecoxib with sodium valproate have an augmentation effect on acute mania in bipolar disorder? A double-blind controlled clinical trial in Iran. ( Ahrari, S; Eslamzadeh, M; Faridhosseini, F; Khadem-Rezaiyan, M; Pourgholami, M; Salimi, Z; Shahini, N; Talaei, A, 2023) |
| " In/outpatients (n = 68) aged 18-70, experiencing mania or hypomania, were assigned to 3 weeks ebselen (600 mg bd) (n = 33) or placebo (n = 35)." | 9.34 | A phase 2a randomised, double-blind, placebo-controlled, parallel-group, add-on clinical trial of ebselen (SPI-1005) as a novel treatment for mania or hypomania. ( Cowen, PJ; Godlewska, BR; Holder, AA; MacDonald, O; Shanyinde, M; Sharpley, AL; Singh, N; Williams, C, 2020) |
| " There is little evidence indicating the efficacy of celecoxib adjuvant therapy in treatmenting of manic episodes of bipolar disorder." | 5.69 | Does celecoxib with sodium valproate have an augmentation effect on acute mania in bipolar disorder? A double-blind controlled clinical trial in Iran. ( Ahrari, S; Eslamzadeh, M; Faridhosseini, F; Khadem-Rezaiyan, M; Pourgholami, M; Salimi, Z; Shahini, N; Talaei, A, 2023) |
| " In parallel, adenosine deficit is increasingly recognized in epilepsy pathophysiology." | 5.41 | Bipolar mania and epilepsy pathophysiology and treatment may converge in purine metabolism: A new perspective on available evidence. ( Boison, D; Daniels, SD, 2023) |
| " In/outpatients (n = 68) aged 18-70, experiencing mania or hypomania, were assigned to 3 weeks ebselen (600 mg bd) (n = 33) or placebo (n = 35)." | 5.34 | A phase 2a randomised, double-blind, placebo-controlled, parallel-group, add-on clinical trial of ebselen (SPI-1005) as a novel treatment for mania or hypomania. ( Cowen, PJ; Godlewska, BR; Holder, AA; MacDonald, O; Shanyinde, M; Sharpley, AL; Singh, N; Williams, C, 2020) |
| "Young Mania Rating Scale (YMRS), Clinical Global Impression Scale (CGI-S), and adverse effects of drugs were assessed at baseline and after 3 and 6 weeks." | 3.11 | Oxcarbazepine versus sodium valproate in treatment of acute mania: a double-blind randomized clinical trial. ( Afzaljavan, F; Akhondzadeh, S; Dastgheib, MS; Mokhber, N; Soltanifar, A; Talaei, A, 2022) |
| "Mania (or manic episodes) is a common symptom of bipolar disorder and is frequently accompanied by hyperactivity and delusions; given the cost and resources available, there is a paucity of evidence for direct comparison of different drugs." | 2.82 | A cumulative Bayesian network meta-analysis on the comparative efficacy of pharmacotherapies for mania over the last 40 years. ( Cao, D; Hong, Y; Huang, W; Wang, L; Wei, H; Xu, J; Zhang, J, 2022) |
| "Although mania defines bipolar I disorder, depressive episodes and symptoms dominate the longitudinal course of, and disproportionately account for morbidity and mortality in, bipolar disorders." | 2.66 | Bipolar disorders. ( Berk, M; Brietzke, E; Goldstein, BI; Kessing, LV; López-Jaramillo, C; Majeed, A; Malhi, GS; Mansur, RB; McIntyre, RS; Nierenberg, AA; Rosenblat, JD; Vieta, E; Vinberg, M; Young, AH, 2020) |
| "Here we developed a novel mania mice model by combining a series of chronic unpredictable rhythm disturbances (CURD), which include disruption of circadian rhythm, sleep deprivation, exposure to cone light, with subsequent interference of followed spotlight, stroboscopic illumination, high-temperature stress, noise disturbance and foot shock." | 1.91 | A novel murine model of mania. ( Chen, B; Cui, L; Feng, Y; Gong, W; Ji, M; Li, B; Li, X; Verkhratsky, A; Wang, S; Wu, X; Xia, M; Zhang, D, 2023) |
| "Novel and effective treatments for mania are needed, and well‑validated animal models are important to reach this goal." | 1.72 | Effect of repeated sodium valproate and topiramate administration on mania‑like behaviors induced by methylphenidate in mice. ( Andreatini, R; Gonçalves, PS; Monteiro Pereira, VC; Pesquero, BO; Valentin, DT, 2022) |
| "Lurasidone is used for treatment of bipolar depression in adults and adolescents." | 1.62 | Lurasidone-Induced Manic Switch in an Adolescent with Bipolar I Disorder: a Case Report. ( Chua, CJM; Nair, SS; Teo, DCL, 2021) |
| "To evaluate external predictability of a population pharmacokinetic model of valproic acid in Thai patients with mania to ensure its appropriateness for use in other clinical settings." | 1.56 | External evaluation of a published population pharmacokinetic model of valproic acid in Thai manic patients. ( Lohitnavy, M; Methaneethorn, J, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 16 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nair, SS | 1 |
| Chua, CJM | 1 |
| Teo, DCL | 1 |
| Kishi, T | 1 |
| Ikuta, T | 1 |
| Matsuda, Y | 1 |
| Sakuma, K | 1 |
| Okuya, M | 1 |
| Nomura, I | 1 |
| Hatano, M | 1 |
| Iwata, N | 1 |
| Akbarzadeh, F | 1 |
| Zolfaghari, M | 1 |
| Fayyazi Bordbar, MR | 1 |
| Dadgar Moghaddam, M | 1 |
| Ziaee, M | 1 |
| Eslamzadeh, M | 2 |
| Mokhber, N | 2 |
| Ayatollahi, ZS | 1 |
| Shayganfard, M | 1 |
| Jamilian, H | 1 |
| Alaghmand, A | 1 |
| Talaei, A | 2 |
| Dastgheib, MS | 1 |
| Soltanifar, A | 1 |
| Akhondzadeh, S | 1 |
| Afzaljavan, F | 1 |
| Çiçekli, MN | 1 |
| Tiryaki, ES | 1 |
| Altun, A | 1 |
| Günaydın, C | 1 |
| Hong, Y | 1 |
| Huang, W | 1 |
| Cao, D | 1 |
| Xu, J | 1 |
| Wei, H | 1 |
| Zhang, J | 1 |
| Wang, L | 1 |
| Gonçalves, PS | 1 |
| Pesquero, BO | 1 |
| Valentin, DT | 1 |
| Monteiro Pereira, VC | 1 |
| Andreatini, R | 1 |
| Li, X | 1 |
| Chen, B | 1 |
| Zhang, D | 1 |
| Wang, S | 1 |
| Feng, Y | 1 |
| Wu, X | 1 |
| Cui, L | 1 |
| Ji, M | 1 |
| Gong, W | 1 |
| Verkhratsky, A | 1 |
| Xia, M | 1 |
| Li, B | 1 |
| Faridhosseini, F | 1 |
| Shahini, N | 1 |
| Salimi, Z | 1 |
| Ahrari, S | 1 |
| Pourgholami, M | 1 |
| Khadem-Rezaiyan, M | 1 |
| Daniels, SD | 1 |
| Boison, D | 1 |
| Varela, RB | 1 |
| Resende, WR | 1 |
| Dal-Pont, GC | 1 |
| Gava, FF | 1 |
| Tye, SJ | 1 |
| Quevedo, J | 1 |
| Valvassori, SS | 1 |
| Methaneethorn, J | 1 |
| Lohitnavy, M | 1 |
| Sharpley, AL | 1 |
| Williams, C | 1 |
| Holder, AA | 1 |
| Godlewska, BR | 1 |
| Singh, N | 1 |
| Shanyinde, M | 1 |
| MacDonald, O | 1 |
| Cowen, PJ | 1 |
| Logan, RW | 1 |
| Ozburn, AR | 1 |
| Arey, RN | 1 |
| Ketchesin, KD | 1 |
| Winquist, A | 1 |
| Crain, A | 1 |
| Tobe, BTD | 1 |
| Becker-Krail, D | 1 |
| Jarpe, MB | 1 |
| Xue, X | 1 |
| Zong, W | 1 |
| Huo, Z | 1 |
| Parekh, PK | 1 |
| Zhu, X | 1 |
| Fitzgerald, E | 1 |
| Zhang, H | 1 |
| Oliver-Smith, J | 1 |
| DePoy, LM | 1 |
| Hildebrand, MA | 1 |
| Snyder, EY | 1 |
| Tseng, GC | 1 |
| McClung, CA | 1 |
| McIntyre, RS | 1 |
| Berk, M | 1 |
| Brietzke, E | 1 |
| Goldstein, BI | 1 |
| López-Jaramillo, C | 1 |
| Kessing, LV | 1 |
| Malhi, GS | 1 |
| Nierenberg, AA | 1 |
| Rosenblat, JD | 1 |
| Majeed, A | 1 |
| Vieta, E | 1 |
| Vinberg, M | 1 |
| Young, AH | 1 |
| Mansur, RB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomised, Parallel Group, Double Blind, Placebo Controlled, Add on Clinical Trial to Investigate Whether the Lithium Mimetic, Ebselen, Can Reduce Symptoms of Hypomania and Mania in Bipolar Patients[NCT03013400] | Phase 2 | 60 participants (Actual) | Interventional | 2017-10-01 | Completed | ||
| Does the IMPase Inhibitor, Ebselen, Affect Emotional Processing and Brain Myo-inositol in Treatment-resistant Depression?[NCT05117710] | Phase 1 | 50 participants (Anticipated) | Interventional | 2021-04-22 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for valproic acid and Hypomania
| Article | Year |
|---|---|
Pharmacological treatment for bipolar mania: a systematic review and network meta-analysis of double-blind randomized controlled trials.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Carbamazepine; Female; | 2022 |
A cumulative Bayesian network meta-analysis on the comparative efficacy of pharmacotherapies for mania over the last 40 years.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Carbamazepine; Dibenzo | 2022 |
Bipolar mania and epilepsy pathophysiology and treatment may converge in purine metabolism: A new perspective on available evidence.
Topics: Adenosine; Adenosine Triphosphate; Antimanic Agents; Bipolar Disorder; Epilepsy; Humans; Hydrocortis | 2023 |
Bipolar disorders.
Topics: Adolescent; Adult; Anticonvulsants; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; B | 2020 |
4 trials available for valproic acid and Hypomania
| Article | Year |
|---|---|
Personality profile and therapeutic response to lithium carbonate and sodium valproate in mania with psychotic features.
Topics: Antimanic Agents; Humans; Lithium; Lithium Carbonate; Mania; Personality; Valproic Acid | 2022 |
Oxcarbazepine versus sodium valproate in treatment of acute mania: a double-blind randomized clinical trial.
Topics: Bipolar Disorder; Double-Blind Method; Humans; Iran; Mania; Oxcarbazepine; Psychiatric Status Rating | 2022 |
Does celecoxib with sodium valproate have an augmentation effect on acute mania in bipolar disorder? A double-blind controlled clinical trial in Iran.
Topics: Antipsychotic Agents; Bipolar Disorder; Celecoxib; Double-Blind Method; Humans; Iran; Mania; Psychia | 2023 |
A phase 2a randomised, double-blind, placebo-controlled, parallel-group, add-on clinical trial of ebselen (SPI-1005) as a novel treatment for mania or hypomania.
Topics: Adult; Aged; Antimanic Agents; Azoles; Bipolar Disorder; Double-Blind Method; Drug Therapy, Combinat | 2020 |
A phase 2a randomised, double-blind, placebo-controlled, parallel-group, add-on clinical trial of ebselen (SPI-1005) as a novel treatment for mania or hypomania.
Topics: Adult; Aged; Antimanic Agents; Azoles; Bipolar Disorder; Double-Blind Method; Drug Therapy, Combinat | 2020 |
A phase 2a randomised, double-blind, placebo-controlled, parallel-group, add-on clinical trial of ebselen (SPI-1005) as a novel treatment for mania or hypomania.
Topics: Adult; Aged; Antimanic Agents; Azoles; Bipolar Disorder; Double-Blind Method; Drug Therapy, Combinat | 2020 |
A phase 2a randomised, double-blind, placebo-controlled, parallel-group, add-on clinical trial of ebselen (SPI-1005) as a novel treatment for mania or hypomania.
Topics: Adult; Aged; Antimanic Agents; Azoles; Bipolar Disorder; Double-Blind Method; Drug Therapy, Combinat | 2020 |
8 other studies available for valproic acid and Hypomania
| Article | Year |
|---|---|
Lurasidone-Induced Manic Switch in an Adolescent with Bipolar I Disorder: a Case Report.
Topics: Adolescent; Antipsychotic Agents; Bipolar Disorder; Drug Therapy, Combination; Humans; Lithium Compo | 2021 |
Comparing the efficacy of aripiprazole as an add-on to valproate with other second-generation antipsychotics in acute mania symptoms in manic patients in Iran.
Topics: Antipsychotic Agents; Aripiprazole; Humans; Iran; Mania; Piperazines; Quinolones; Treatment Outcome; | 2022 |
GLP-1 agonist liraglutide improves ouabain-induced mania and depressive state
Topics: Animals; Antioxidants; Glucagon-Like Peptide 1; Glutathione; Glycogen Synthase Kinase 3 beta; Liragl | 2022 |
Effect of repeated sodium valproate and topiramate administration on mania‑like behaviors induced by methylphenidate in mice.
Topics: Animals; Antimanic Agents; Central Nervous System Stimulants; Mania; Methylphenidate; Mice; Topirama | 2022 |
A novel murine model of mania.
Topics: Animals; Bipolar Disorder; Disease Models, Animal; Humans; Mania; Mice; Sleep Deprivation; Valproic | 2023 |
HDAC inhibitors reverse mania-like behavior and modulate epigenetic regulatory enzymes in an animal model of mania induced by Ouabain.
Topics: Animals; Behavior, Animal; Bipolar Disorder; Butyric Acid; Corpus Striatum; Disease Models, Animal; | 2020 |
External evaluation of a published population pharmacokinetic model of valproic acid in Thai manic patients.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Computer Simulation; Drug Monitoring; Female; Humans; Male | 2020 |
Valproate reverses mania-like behaviors in mice via preferential targeting of HDAC2.
Topics: Animals; Histone Deacetylase 2; Histone Deacetylase Inhibitors; Humans; Induced Pluripotent Stem Cel | 2021 |